📊 BDRX Key Takeaways
Is Biodexa Pharmaceuticals Plc (BDRX) a Good Investment?
Biodexa Pharmaceuticals has virtually no financial data available in SEC filings, indicating either pre-revenue status, severe reporting deficiencies, or inactive operations. With only 1 metric available out of comprehensive financial reporting requirements, the company presents extreme information risk and appears unable to demonstrate basic operational or financial viability.
Biodexa remains a pre-revenue clinical-stage biotech with no commercial revenue in 2024, a net loss of about £5.7 million, and negative operating cash flow of about £12.3 million. While the balance sheet improved through equity financing and the company reported additional cash resources and grant support in May 2025, the core fundamentals still show a business dependent on external capital, with auditors and management explicitly highlighting going-concern risk.
Why Buy Biodexa Pharmaceuticals Plc Stock? BDRX Key Strengths
- No strengths identified
- Total equity improved to about £8.3 million at December 31, 2024 from £4.7 million a year earlier after financing activity
- Debt burden was relatively low, with borrowings of about £0.7 million at year-end 2024 and about $0.5 million reported in May 2025
- The eRapa Phase 3 program had meaningful non-dilutive support, including cash in escrow and an undrawn CPRIT grant that management said substantially funds the study
BDRX Stock Risks: Biodexa Pharmaceuticals Plc Investment Risks
- Complete absence of revenue and profitability data
- No balance sheet, cash flow, or liquidity metrics reported
- Critical information vacuum prevents fundamental analysis
- Zero insider trading activity suggests lack of management confidence
- Severe potential going concern issues given data gaps
- No commercial revenue in 2024 and continuing operating losses indicate weak underlying business sustainability
- Operating cash burn worsened materially in 2024, with net cash used in operations rising to about £12.3 million versus about £6.8 million in 2023
- Management and auditors disclosed substantial doubt about the company's ability to continue as a going concern without additional financing
Key Metrics to Watch
- Revenue recognition and product commercialization timeline
- Cash position and runway to profitability
- SEC filing compliance and data completeness
- Quarterly cash burn versus unrestricted cash and near-term funding runway
- Clinical progress and funding efficiency of the eRapa Phase 3 program, including use of grant-backed capital
Biodexa Pharmaceuticals Plc (BDRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BDRX Profit Margin, ROE & Profitability Analysis
BDRX vs Healthcare Sector: How Biodexa Pharmaceuticals Plc Compares
How Biodexa Pharmaceuticals Plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Biodexa Pharmaceuticals Plc Stock Overvalued? BDRX Valuation Analysis 2026
Based on fundamental analysis, Biodexa Pharmaceuticals Plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Biodexa Pharmaceuticals Plc Balance Sheet: BDRX Debt, Cash & Liquidity
BDRX Revenue Growth, EPS Growth & YoY Performance
BDRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Biodexa Pharmaceuticals Plc (CIK: 0001643918)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BDRX
What is the AI rating for BDRX?
Biodexa Pharmaceuticals Plc (BDRX) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BDRX's key strengths?
Claude: . ChatGPT: Total equity improved to about £8.3 million at December 31, 2024 from £4.7 million a year earlier after financing activity. Debt burden was relatively low, with borrowings of about £0.7 million at year-end 2024 and about $0.5 million reported in May 2025.
What are the risks of investing in BDRX?
Claude: Complete absence of revenue and profitability data. No balance sheet, cash flow, or liquidity metrics reported. ChatGPT: No commercial revenue in 2024 and continuing operating losses indicate weak underlying business sustainability. Operating cash burn worsened materially in 2024, with net cash used in operations rising to about £12.3 million versus about £6.8 million in 2023.
What is BDRX's revenue and growth?
Biodexa Pharmaceuticals Plc reported revenue of N/A.
Does BDRX pay dividends?
Biodexa Pharmaceuticals Plc does not currently pay dividends.
Where can I find BDRX SEC filings?
Official SEC filings for Biodexa Pharmaceuticals Plc (CIK: 0001643918) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BDRX's EPS?
Biodexa Pharmaceuticals Plc has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is BDRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Biodexa Pharmaceuticals Plc has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is BDRX stock overvalued or undervalued?
Valuation metrics for BDRX: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy BDRX stock in 2026?
Our dual AI analysis gives Biodexa Pharmaceuticals Plc a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BDRX's free cash flow?
Biodexa Pharmaceuticals Plc's operating cash flow is N/A, with capital expenditures of N/A.
How does BDRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio N/A (avg: 2).